Practical consensus recommendations on ovarian suppression in early breast cancer (adjuvant)

被引：2

作者：

Singhal, M. ^{[1
]}

Sahoo, T. P. ^{[6
]}

Aggarwal, S. ^{[2
]}

Singhvi, A. ^{[7
]}

Kaushal, V. ^{[8
]}

Rajpurohit, S. ^{[3
]}

Parthasarthi, K. M. ^{[4
]}

Vora, A. ^{[5
]}

Ganvir, M. ^{[2
]}

Gupta, S. ^{[9
]}

Parikh, Purvish M. ^{[10
]}

机构：

[1] Indraprastha Apollo Hosp, Dept Med Oncol, New Delhi, India

[2] Sir Ganga Ram Hosp, Dept Med Oncol, New Delhi, India

[3] RGCI, Dept Med Oncol, New Delhi, India

[4] Dharamshila Canc Hosp, Dept Med Oncol, New Delhi, India

[5] Hope Clin, Dept Med Oncol, New Delhi, India

[6] Chirayu Canc Hosp, Dept Med Oncol, Bhopal, India

[7] Choitram Hosp, Dept Med Oncol, Indore, Madhya Pradesh, India

[8] RCC, Dept Radiat Oncol, Rohtak, Haryana, India

[9] Tata Mem Hosp, Dept Med Oncol, Mumbai, Maharashtra, India

[10] Shalby Canc & Res Inst, Dept Oncol, Mumbai, Maharashtra, India

来源：

SOUTH ASIAN JOURNAL OF CANCER | 2018年 / 7卷 / 02期

关键词：

AI; exemestane; LHRH agonist; menopausal status; monitoring; tamoxifen;

D O I：

10.4103/sajc.sajc_125_18

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Substantial survival benefits exist for patients with early-stage breast cancer who undergo treatment with single-modality ovarian suppression, but its value is uncertain. Expert oncologist discussed to determine whether additional benefits exist with ovarian suppression plus multiple adjuvant therapy which provides a new treatment option that reduces the risk of recurrence in early breast cancer. This expert group used data from published literature, practical experience and opinion of a large group of academic oncologists to arrive at this practical consensus recommendations for the benefit of community oncologists.

引用

页码：151 / 155

页数：5

共 53 条

[1] Abe O, 2005, LANCET, V365, P1687, DOI 10.1016/s0140-6736(05)66544-0
[2] Spectrum of breast cancer in Asian women
Agarwal, Gaurav
Pradeep, P. V.
Aggarwal, Vivek
Yip, Cheng-Har
Cheung, Polly S. Y.
[J]. WORLD JOURNAL OF SURGERY, 2007, 31 (05) : 1031 - 1040
[3] ALTEKRUSE SF, 1975, SEER CANC STAT REV
[4] [Anonymous], 1992, Lancet, V339, P1
[5] Badwe R A, 1990, Indian J Cancer, V27, P220
[6] Baum M, 2003, Cancer, V98, P1802
[7] Beatson GT, 1896, LANCET, V15, P153, DOI [DOI 10.1016/S0140-6736(01)72307-0, 10.1016/S0140-6736(021)72384-7]
[8] Effect of endocrine treatment on sexuality in premenopausal breast cancer patients:: A prospective randomized study
Berglund, G
Nystedt, M
Bolund, C
Sjödén, PO
Rutquist, LE
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (11) : 2788 - 2796
[9] OVARIAN ABLATION VERSUS GOSERELIN WITH OR WITHOUT TAMOXIFEN IN PRE-PERIMENOPAUSAL PATIENTS WITH ADVANCED BREAST-CANCER - RESULTS OF A MULTICENTRIC ITALIAN STUDY
BOCCARDO, F
RUBAGOTTI, A
PERROTTA, A
AMOROSO, D
BALESTRERO, M
DEMATTEIS, A
ZOLA, P
SISMONDI, P
FRANCINI, G
PETRIOLI, R
SASSI, M
PACINI, P
GALLIGIONI, E
[J]. ANNALS OF ONCOLOGY, 1994, 5 (04) : 337 - 342
[10] COMBINATION CHEMOTHERAPY AS AN ADJUVANT TREATMENT IN OPERABLE BREAST-CANCER
BONADONNA, G
BRUSAMOLINO, E
VALAGUSSA, P
ROSSI, A
BRUGNATELLI, L
BRAMBILLA, C
DELENA, M
TANCINI, G
BAJETTA, E
MUSUMECI, R
VERONESI, U
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 1976, 294 (08) : 405 - 410

← 1 2 3 4 5 6 →